N@N

Inhibitex to Present at Two Upcoming Conferences

_{//health-fitness.news-articles.net/content/2011/ .. itex-to-present-at-two-upcoming-conferences.html}
^{Published in Health and Fitness on Thursday, August 25th 2011 at 13:42 GMT by Market Wire}  

ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced that executive management is scheduled to present an overview of the company and its pipeline at the following two conferences:

-- Joseph M. Patti, senior vice president of research and development and chief scientific officer, will present at the Stifel Nicolaus Healthcare Conference, on Wednesday, September 7, 2011 at 2:40 pm EDT. The conference is being held at The Four Seasons Hotel in Boston, Massachusetts.

-- Russell H. Plumb, president and chief executive officer, will present at the JMP Securities Fifth Annul Healthcare Conference, on Wednesday, September 28, 2011 at 8:30 am EDT. The conference is being held at The St. Regis New York Hotel in New York, New York.

The presentations will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at[ www.inhibitex.com ]. Shortly following the live webcast a replay will also be available on the Company website.

About Inhibitex

Inhibitex, Inc. is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Companya™s clinical-stage pipeline currently includes two Phase 2 development programs; INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections and FV-100, a nucleoside analogue in development for the treatment of shingles-associated pain. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM^® protein platform to Pfizer for the development of a staphylococcal vaccine, which is currently being evaluated in a Phase 1 clinical trial. For additional information about the Company, please visit [ www.inhibitex.com ].

Inhibitex^® and MSCRAMM^® are registered trademarks of Inhibitex, Inc.